FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 02/2024”.
The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.
As of the end of February 2024 we identify the following current VC trends in the United States:
- Total Healthcare & Life Sciences funding has reached EUR 5,224m
- Biotech received 58% of the total investment volume (EUR 3,040m) with oncology being the leading indication (30%)
- In February Areteia Therapeutics secures the highest transaction volume with EUR 392m, followed by Freenome with EUR 235m and BioAge with EUR 178m
- Premji Invest (United States) is the most active investor (by deal volume), followed by Novo Holdings (Denmark) and Sands Capital (United States)
To access the full report, please click here.
By Mathias Klozenbücher und Johannes Link.
LinkedIn